UBX News and Press, Unity Biotechnology Inc. From 07/06/21

Improvement in Visual Acuity and Central Subfield Thickness observed in diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD) patients treated with UBX1325 UBX1325 advances to Phase 2a study in DME patients as a potential alternative to anti-VEGF therap...

Mario13/E+ via Getty Images Intellia has a “more de-risked platform” now: Jefferies Intellia Therapeutics (NTLA) and Regeneron (REGN) have climbed sharply in the pre-market after the duo marked a milestone in CRISPR gene-editing with interim results for NTLA-2001 in transthyreti...

-  UBX1325 demonstrates favorable tolerability in Phase 1 safety study with initial evidence of relevant biological activity -  Phase 2a proof-of-concept study initiated in patients with diabetic macular edema; data expected first half of 2022 -  Cash ...

UBX1325’s selective elimination of senescent cells represents a novel approach for the treatment of diabetic retinopathy and macular edema Preclinical data featured in poster presentations at the ARVO 2021 Annual Meeting SOUTH SAN FRANCISCO, Calif., May 01, 2021 (GL...

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, will present preclinical data on its lead clinical candidate, UBX1325,...

Anti-aging concern Unity Biotechnology, Inc. saw its share price collapse after its lead candidate (UBX0101) flunked a Phase 2 study in August 2020. The setback forced a restructuring with a pivot away from musculoskeletal targets and towards ophthalmologic and neurologic indications....

SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 3...

Gainers: [[RUBY]] +16.8%. [[SALM]] +7.5%. [[NXPI]] +5%. [[CHMA]] +3.5%. [[UBX]] +2.7%.Losers: [[CLPS]] -4.2%. [[AMTX]] -3.9%. [[VRAY]] -3.2%. [[TPIC]] -2.8%. [[EOLS]] -2.5%. For further details see: NXPI, TPIC, EOLS and UBX among after-hours movers

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that Alexander Nguyen has officially joined UNITY as g...

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that members of its senior management team will par...